. AD is genetically heterogeneous, and can be caused by one or more of several genes as well as environ mental factors. Familial AD (FAD), which accounts for less than 1% of all AD cases, is caused by rare mutations in genes encoding amyloid precursor protein (APP), presenilin 1 (PSEN1) and PSEN2 (REFS 1, 3) . Numerous genes are associated with sporadic late-onset AD. The apolipoprotein E4 allele is the single strongest genetic risk factor for sporadic AD 4 . Cleavage of APP by β-secretase and the γ-secretase complex -which consists of PSEN1 or PSEN2, anterior pharynx defective 1, presenilin enhancer 2 and nicastrin -leads to the generation of the extracellular amyloid-β (Aβ) peptide. This peptide fragment is prone to aggregation and forms amyloid plaques that can be detected in the post-mortem brain samples of patients with AD 5, 6 . In addition to amyloid plaques, neurofibrillary tangles made up of hyperphosphorylated aggregates of tau, a microtubule-associated protein, are also observed in post-mortem brain samples of patients with AD 5, 6 . By contrast, HD is a monogenic disorder that occurs as a result of autosomal dominant inheritance and is caused by a CAG repeat that expands to 36 copies or more in the gene encoding the huntingtin (HTT) protein 2 , resulting in an expansion of the polyglutamine tract. Furthermore, the length of the CAG tract is directly correlated with disease onset, with longer expansions leading to earlier onset of HD 2 . The enzymes β-secretase, γ-secretase and the Aβ peptide are well-validated therapeutic targets in AD 7 , and mutant HTT is a promising target in HD 8, 9 . However, these targets are not shared between AD and HD, and will therefore not be the focus of this Review.
Microtubule
One of the principal components of the cytoskeleton. Microtubules are hollow, dynamic rod structures that participate in determining cell shape, cell locomotion and intracellular transport processes.
CAG repeat
A trinucleotide repeat of cytosine, adenine and guanine (CAG) that results in the expression of a chain of glutamines in the protein sequence.
Polyglutamine tract
The part of a protein that is entirely composed of the amino acid glutamine, resulting from a cytosine, adenine and guanine (CAG) repeat in the corresponding gene.
Medium spiny neurons
A type of GABA (γ-aminobutyric acid)-ergic inhibitory neurons that have a key role in movement initiation and control. They represent ~90% of the neurons in the striatum of the brain.
CA1 zone
Cornu ammonis area 1. An area of the hippocampus that is composed of densely packed pyramidal cells.
Entorhinal cortex
An area located in the medial temporal lobe of the brain. Neurons from this area project to the hippocampus. The entorhinal cortex is involved in memory formation, in particular spatial memory.
Ubiquitin-proteasome system
A major pathway for the intracellular degradation of proteins. Substrates are conjugated to the peptide ubiquitin and transported to the proteasome, an organelle that has proteolytic activity and breaks the polypeptide chain into single amino acids.
Neurotrophic factor
A peptide secreted by brain tissues to guide axonal growth that is responsible for neuronal growth, differentiation and survival.
At a neuropathological level, these two diseases are initially characterized by a specific loss of certain neuronal subtypes. In HD it is the medium spiny neurons in the striatum that undergo atrophy in early stages of the disease, whereas in AD large pyramidal neurons in the CA1 zone of the hippocampus as well as neurons in the basal forebrain and the entorhinal cortex are affected in early stages of the disease [10] [11] [12] . The process of neuronal dysfunction and death is progressive, and early changes are followed by a more widespread atrophy of the brain 10, 13 . Considerable progress has been made in the elucidation of mechanisms that lead to neurodegeneration in AD and HD. There is evidence for the aberrant phosphorylation, palmitoylation and acetylation of disease-causing proteins, protein misfolding, a failure of the ubiquitin-proteasome system or autophagy to clear disease-causing proteins, as well as changes in NMDA (N-methyl-d-aspartate) receptor activity at the synapse. Additional mechanisms include alterations in levels of brain-derived neurotrophic factor (BDNF) and neuronal growth factor (NGF) as well as changes in levels of associated receptors and trafficking pathways, and increased activity of caspases in both disorders 5, 6, 9, 14 (TABLE 1) .
Although there are no treatments available that slow or halt neuronal degeneration and neuronal death, the analysis of disease-triggering pathways has led to the identification of common drug targets for AD and HD. These similarities have not been commonly appreciated by the HD or AD research communities, but we believe that an understanding of these similarities could lead to the development of drugs that could be used for both disorders. In this Review, we describe these shared pathways and therapeutic targets and rank them with target-validation scores based on a scale developed by the Cure Huntington's Disease Initiative (CHDI) 15 (TABLE 2), which we apply to both diseases for direct comparison (see the HD Research Crossroads website (registration required)). Potential therapeutic targets are hereby ranked by their degree of validation, from 1.0 (for a gene and/or protein that is linked to a diseaserelevant biological mechanism) to 6.0 (if therapeutic modulation of the target demonstrates efficacy in a Phase III clinical trial). Although well-studied targets will automatically be ranked higher in this system than understudied targets, we believe that our ranking can identify common well-validated targets as well as knowledge gaps that warrant further studies.
In most cases it is unknown whether the modulation of targets will have a disease-modifying effect or whether it will only lead to the alleviation of symptoms, and the target-validation score does not discriminate between these possibilities. Long-term clinical studies will be necessary to clarify whether compounds will be diseasemodifying, and we believe that these could initially be carried out in individuals carrying the genetic mutation that causes HD, as this population is well defined and alterations in the course of the disease can be determined at very early stages of the disease 16 . HD is the most common neurodegenerative disorder that has a purely genetic cause, whereas AD is the most common neurodegenerative disease overall 1, 2 . As many of the pathways and targets described here are also implicated in other diseases -such as Parkinson's disease, dementia with Lewy bodies or ataxias -HD could serve as a general model for neurodegeneration, for which well-defined animal models are available for preclinical studies and end points for clinical trials are well established 16, 17 . The Enroll-HD study that is currently underway will provide a registry of HTT mutation carriers worldwide, and may serve as a resource for recruiting patients into clinical trials (see the Enroll-HD website).
Targeting synaptic dysfunction
Excitotoxicity has been implicated as a cause of neuronal death in both HD and AD. The NMDA subtype of glutamate receptors is thought to be a major contributor to excitotoxic cell death because of its high permeability to calcium 18 . NMDA receptor (NMDAR) subunit 2A (NR2A; also known as GRIN2A) and NR2B (also known as GRIN2B) differ in their sensitivities to agonists and antagonists, their channel-gating properties, and in their localization. NR2A-containing NMDARs are generally found at the synapse, whereas NR2B-containing NMDARs are predominantly localized at extrasynaptic sites 18 . Enhanced activation of extrasynaptic NR2B-containing NMDARs is common in both HD and AD.
Aberrant extrasynaptic NMDAR activity. The presence of mutant HTT and APP alters the subcellular distribution of NMDARs 18, 19 . In mouse models of both diseases, deficits in trafficking mechanisms increase levels of NR2B on the cell surface and decrease NR2B internalization 18 . Increased levels of NR2B on the cell surface result in enhanced NMDAR-mediated currents in mouse models of HD and AD 19 . Both wild-type HTT and tau, a neuronal protein that stabilizes microtubules, are involved in NR2B trafficking as well as the recruitment of kinases to NMDARs at the cell surface. Mutant HTT disrupts these processes, resulting in altered tyrosine phosphorylation of NR2B and enhanced NMDARmediated excitotoxicity 20 . Similarly, Aβ-induced NMDAR dysfunction is mediated by FYN, a tyrosine kinase that phosphorylates NR2B 21, 22 and mediates its insertion into the plasma membrane 23 -thereby increasing the levels of NR2B on the cell surface.
The activation of extrasynaptic NR2B-containing NMDARs also leads to the dephosphorylation and inhibition of the signalling pathway mediated by cyclic AMP-responsive element-binding protein and peroxisome proliferator-activated receptor-γ co-activator 1α, which makes cells expressing mutant HTT more susceptible to cell death 24 (FIG. 1) . Furthermore, enhanced activation of extrasynaptic NMDARs leads to excessive influx of calcium into the cell, which results in inappropriate activation of enzymes (such as calpains and other calcium-regulated enzymes) and mitochondrial dysfunction; this leads to apoptosis 18 . Activation of extrasynaptic NMDARs may also underlie the cognitive impairment that is observed in patients with HD and AD. Long-term potentiation (LTP), a measure of synaptic plasticity, is thought to be a
Synaptic plasticity
A process involved in learning and memory, whereby synapses gauge the intensity of their response to an incoming signal. It occurs as a result of the modulation of the number or sensitivity of receptors at the synapse or changes in the quantity of neurotransmitters released.
Morris water maze
An experiment that is used to assess spatial learning and memory in rodents. Rodents are placed in a circular pool of water, and by learning spatial markers they can identify the location of a hidden platform and escape from the water. mechanism underlying learning and memory. In mouse models of AD and HD, neurons derived from affected brain regions have defective LTP 25, 26 . Furthermore, the activation of extrasynaptic NMDARs in a mouse model of AD promotes β-secretase-mediated cleavage of APP, which results in increased levels of Aβ that are directly correlated with the severity of the cognitive deficit 27 . The presence of Aβ oligomers -early intermediates in the Aβ aggregation pathway -has in turn been associated with increased activation of extrasynaptic NMDARs, which could cause a feedback loop that leads to synaptic dysfunction 28 . However, the strongest evidence for the role of extrasynaptic NMDARs in cognitive impairment is the effectiveness of the NMDAR blocker memantine in rodent models of HD and AD as well as in patients with AD 24,29-31 .
Therapeutic approaches. Inhibition of extrasynaptic NMDARs can be achieved using memantine. At a low dose (1 mg per kg, which is a human equivalent dose of 3 mg per m 2 ) memantine blocks extrasynaptic but not synaptic NMDAR activity in a mouse model of HD, whereas high doses of memantine (30 mg per kg, which is a human equivalent dose of 90 mg per m 2 ) inhibit both synaptic and extrasynaptic NMDAR activity (FIG. 1) . A low dose of memantine rescues neuropathological and behavioural phenotypes as well as electrophysiological abnormalities in mouse models of HD. By contrast, administration of a high dose of memantine worsens these symptoms 24, 29 . Similarly, the administration of a low dose of memantine in a mouse model of AD corrected defects in learning and memory tasks, such as performance in the Morris water maze test and passive avoidance learning 30 . Memantine treatment has also been tested in patients with AD, and is now approved by the US Food and Drug Administration for this indication (Namenda XR, Forest Laboratories). In clinical trials, patients with AD who received 28 mg of memantine (an extended-release formulation) for 24 weeks had a significantly reduced decline in cognitive symptoms in two measures of cognitive performance compared to patients receiving placebo. Longer studies are needed, however, to determine whether the effects of memantine are purely symptomatic or disease-modifying. Nevertheless, the improvements seen in patients with AD are encouraging, and NR2B-containing NMDARs are currently the best validated of the shared therapeutic targets between AD and HD, with target-validation scores of 6.0 and 4.0, respectively (See Supplementary information S1 (table)). In view of open-label studies in which memantine shows some potential therapeutic benefit in patients with HD, further clinical trials with memantine should be considered [32] [33] [34] .
Non-neuronal contributions to excitotoxicity
Another striking similarity between AD and HD is the presence of activated microglia that act as markers of inflammation 5, 14 . Microglia produce quinolinic acid, which is a metabolite of the tryptophan degradation pathway and a selective NMDAR agonist; it elicits symptoms that are similar to HD when it is injected into the striatum of rodents, and symptoms that are similar to AD when it is injected into the nucleus basalis of rodents 35 . Furthermore, a recent study has demonstrated that inhibiting kynurenine 3-monooxygenase, an enzyme involved in the metabolic pathway that generates quinolinic acid, can ameliorate excitotoxicity and disease phenotypes in mouse models of AD and HD 35 .
Modulating neurotrophic factors and receptors
Neurotrophic factors, including NGF and BDNF, are secreted peptides that have prominent roles in neuronal development and health, as well as in the function of the regions of the brain that are most affected in patients with AD and HD 36 . NGF specifically binds to neurotrophic tyrosine kinase receptor type 1 (NTRK1; also known as TRKA) receptors, whereas BDNF recognizes NTRK2 (also known as TRKB) to activate downstream signalling pathways. In addition, both neurotrophic factors bind to the nerve growth factor receptor (NGFR; also known as p75NTR) with lower affinity, which is associated with pro-death signalling following neuronal injury 36 (FIG. 2) . The unprocessed precursor forms of NGF and BDNF (pro-NGF and pro-BDNF, respectively) also bind to p75NTR, leading to apoptosis 36 . Alterations in the levels of NGF and BDNF, the levels and localization of cognate receptors and changes in the pathways activated by these neurotrophins have been implicated in the pathogenesis of HD and AD (FIG. 2; Supplementary information S1 (table) ).
Increasing BDNF levels as a therapeutic approach.
Reduced levels of BDNF have been observed in the striatum and hippocampus of patients suffering from HD and AD, respectively 37, 38 . Polymorphisms in the BDNF gene have been positively associated with the age of onset of AD in some studies [39] [40] [41] , although this association is controversial in some studies but not others [42] [43] [44] . Similarly, data on an association between BDNF polymorphisms and the age of onset in HD have also been conflicting 45, 46 . The ability to increase BDNF levels through exercise is well documented 47 . Using transgenic mice harbouring mutations in APP and PSEN1 genes (APP/ PSEN1-transgenic mice), it has been shown recently that exercise increases BDNF levels and prevents a decline in spatial learning and memory through the improvement of LTP in the hippocampus 48 . The beneficial effects of BDNF overexpression using genetically modified mesenchymal stem cell transplantation, viral-mediated expression or intracranial injections of BDNF in different rodent models of HD and AD have validated BDNF as a therapeutic target and led to target-validation scores of 4.5 and 4.0 for AD and HD, respectively (Supplementary information S1 (table)). Overexpression of BDNF protects against neurotoxicity, prevents the loss of neurons, corrects motor dysfunction, improves procedural learning and corrects synaptic plasticity in mouse models of AD and HD [49] [50] [51] . Increasing BDNF levels in a nonhuman primate model of AD also improved hippocampal learning and ameliorated neuronal death with no observable adverse effects 52 . Pharmacological agents that are currently used or being investigated for other clinical applications, such as lithium or the ampakine CX929, can increase BDNF levels by increasing its expression and promoting its 53, 54 . A Phase II clinical trial studying the effect of lithium treatment in patients with AD is currently underway (ClinicalTrials. gov identifier: NCT00088387), and in a small cohort of patients lithium reduced the progression from mild cognitive impairment to AD 55 . In addition to increasing BDNF levels, lithium inhibits the hyperphosphorylation of tau mediated by glycogen synthase kinase 3β (GSK3β), and activates autophagy as well as pro-survival signalling mediated by cyclic AMP-responsive element-binding protein [56] [57] [58] [59] (FIG. 2) . Owing to these multiple effects, lithium is a suboptimal tool compound for investigating specific pathways but it remains a potential therapeutic for both AD and HD.
Trafficking defects in HD and AD: targeting microtubuleassociated proteins. Striatal medium spiny neurons rely on the release of BDNF from innervating cortical neurons for their normal functioning and survival, which means that axonal trafficking of BDNF from the cell body of cortical neurons to the synapse is an important process in ensuring the survival and functioning of medium spiny neurons 60 . Defects in intracellular trafficking have been suggested as a cause for the reduced BDNF levels in the brains of patients with HD or AD 60, 61 . Interestingly, polymorphisms in the BDNF gene that are associated with an increased risk of AD and reduced age of onset of HD impair the binding of pro-BDNF to huntingtinassociated protein 1 (HAP1), which is necessary for the intracellular trafficking of pro-BDNF 60, 62 . These polymorphisms could therefore lead to reduced BDNF levels in both diseases (FIG. 2) .
HTT and tau are predominantly found in the cytoplasm, where they colocalize with microtubules and vesicular structures and associate with proteins that are involved in intracellular trafficking 61, 63 . Wild-type HTT interacts with HAP1, which in turn interacts with proteins that are essential for intracellular trafficking, such as kinesin and the p150 subunit of dynactin (DCTN1) 60, 63 . Similarly, tau regulates axonal transport by inhibiting the motor activity of kinesin and dynein (FIG. 2; Supplementary information S1 (table)) 63, 64 . The velocity and efficiency of the transport of BDNFcontaining vesicles are reduced in the presence of mutant HTT and PSEN1, as well as hyperphosphorylated tau 60, 61 . In neuronal cultures and post-mortem extracts of brain tissue taken from patients with HD, mutant HTT binds to HAP1 with increased affinity, which in turn disrupts the binding of HAP1 to kinesin and weakens the HAP1-DCTN1 interaction, thereby reducing the efficiency and velocity of the transport of BDNF-containing vesicles 60 . Interestingly, HAP1 deficiency also affects kinesindependent transport of APP, which suggests that HAP1 may have a role in the pathogenesis of AD 65 . Mutations in PSEN1 that are associated with FAD deregulate GSK3β, leading to hyperphosphorylation of tau and its detachment from microtubules, which results in cytoskeletal collapse and deficits in axonal transportboth of which contribute to the pathogenesis of AD 61, 66, 67 
(FIG. 2).
Although there are currently no therapies available that can ameliorate trafficking deficits to increase BDNF levels, the BDNF trafficking pathway has many potential therapeutic targets -such as HAP1, kinesin, dynein and/or DCTN1 and microtubules -that could be modified for the treatment of HD and AD.
Inhibitors of histone deacetylases (HDACs), which are currently being used as cancer therapeutics 68 , influence axonal transport through increased acetylation of α-tubulin, which enhances its binding to kinesin 4, 69 . Therefore, the effects of HDAC inhibitors which is released from the presynaptic neuron, or by the NMDAR agonist quinolinic acid (QA), which is a product of tryptophan metabolism in microglia. Although glutamate-mediated activation of synaptic NMDARs promotes neuronal survival, QA leads to excessive NMDAR activation and synaptic dysfunction. The levels of QA generation can be altered through inhibition of kynurenine 3-monooxygenase, an enzyme involved in tryptophan metabolism. An imbalance in levels of synaptic and extrasynaptic NMDARs is seen in both Huntington's disease and Alzheimer's disease. The huntingtin (HTT) protein and microtubule-associated protein tau are involved in regulating the trafficking of NMDAR subunit 2B (NR2B) to the extrasynaptic membrane. NR2B-containing NMDARs are hyperphosphorylated as mutant HTT and tau increase the recruitment of kinases to NR2B. An increase in the levels and phosphorylation of NR2B-containing NMDARs leads to an increase in extrasynaptic NMDA currents that triggers cell death through multiple pathways. Two major pathways leading to cell death in Huntington's disease and Alzheimer's disease are represented in this figure: inhibition of cyclic AMP-responsive element-binding protein (CREB) phosphorylation, which leads to inhibition of pro-survival pathways; and an increase in calcium influx, which leads to mitochondrial dysfunction.
Caspase 6
A member of the cysteineaspartic protease (caspase) family that has essential roles in programmed cell death (apoptosis).
on kinesin-and/or dynein-mediated axonal transport deserve greater investigation as a potential therapy for HD. The modulation of HAP1 binding to mutant HTT would probably be harder to achieve, as the strengthening of a protein-protein interaction is generally not considered to be a druggable intervention. However, drugs that bind and/or stabilize microtubules -such as paclitaxel and epothilones, which are currently used as a form of cancer therapy [70] [71] [72] -could be tested in mouse or rodent models of HD and AD to validate therapeutic targets in axonal transport pathways more effectively (Supplementary information S1 (table) ). Epothilone D, a microtubule-binding agent from the epothilone natural product family, has been shown to penetrate the bloodbrain barrier and increase microtubule stability in the central nervous system of tau transgenic mice 71 . The identification and evaluation of agents that bind microtubules is therefore a promising area of research for the treatment of neurodegenerative disorders that have impaired axonal transport, such as HD and AD.
Increasing NGF is beneficial. A reduction in the levels of mature NGF is observed in the basal forebrain of aged animals and in rodent models of AD, as well as in patients with AD 73 . However, the levels of NGF in patients with HD have not been reported. Nevertheless, the overexpression of NGF in model systems of HD and AD has beneficial effects that are similar to BDNF overexpression. Rat models of AD and mouse models of HD that are transplanted with NGF-loaded microspheres in the forebrain show significant improvements in learning and memory tasks, and improved survival of cholinergic neurons 74, 75 . Intrastriatal transplantation of genetically engineered mesenchymal stem cells expressing NGF and the administration of an amplifier of NGF into transgenic mouse models of HD slows neurodegeneration and rescues behavioural deficits 50 . Therapeutic clinical trials assessing the effects of increasing NGF levels in patients with AD are underway. In a Phase I clinical study, the implantation of modified fibroblasts expressing human NGF in the basal forebrain of patients with AD resulted in a decrease in the rate of cognitive decline 76 . Currently, therapeutic options that are less invasive are being explored, including the intranasal delivery of recombinant NGF, which rescued behavioural and neuropathological defects in a mouse model of AD 77 . NGF -like BDNF -is therefore a highly validated target for AD and HD, with target-validation scores of 4.5 and 4.0, respectively (Supplementary information S1 (table)).
Activating TRK and reducing p75NTR signalling as a therapeutic strategy. In animal models of AD and HD as well as in patients suffering from these diseases, p75NTR levels are increased. In patients and animal models of AD there is a decrease in TRKA levels, and in patients and animal models of HD there is a decrease in TRKB levels 73, 78 . Neurotrophin-mediated cell death that occurs through the activation of p75NTR is mediated through caspase 6 activity 79 , and this enzyme has emerged as a therapeutic target for both AD and HD in several studies (described below and in Supplementary information S1 (table)).
Neurotrophin signalling through TRK receptors activates pro-survival pathways, such as the phosphoinositide 3-kinase (PI3K)-AKT signalling pathway. However, reduced signalling through TRK receptors results in increased GSK3β activity, which has been implicated in the prevention of LTP, the induction of microgliamediated inflammation and the promotion of neuronal death in animal models of AD and HD 57, 80 . In AD increased GSK3β signalling also increases tau phosphorylation and Aβ production, whereas in HD increased GSK3β activity enhances the toxicity of mutant HTT 57, 80 . Figure 2 | Therapeutic targets in the neurotrophin pathway. Levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) are reduced in both Huntington's disease (HD) and in Alzheimer's disease (AD). Presynaptically, the huntingtin (HTT) protein, amyloid precursor protein (APP) and microtubule-associated protein tau influence trafficking mechanisms by interacting with huntingtin-associated protein 1 (HAP1), kinesin, and dynein or dynactin, which influences the binding of HAP1, kinesin and dynein or dynactin to microtubules. The unprocessed precursor forms of BDNF and NGF -pro-BDNF and pro-NGF, respectively -are processed by unknown proteases to generate mature BDNF and NGF. Furthermore, levels of neurotrophic tyrosine kinase receptor type 1 (TRKA) and TRKB are decreased in AD and HD, respectively. Signalling through TRK receptors is reduced, thereby increasing glycogen synthase kinase 3β (GSK3β) activity and enhancing cell death pathways. Increased levels of low-affinity nerve growth factor receptor (p75NTR) and signalling mediated by pro-BDNF and pro-NGF also triggers cell death. Therapeutics that have been examined to target this pathway include epothilone D, BDNF, NGF, glucocorticoids and lithium. PI3K, phosphoinositide 3-kinase.
Apoptotic cell death
Also known as programmed cell death. A mechanism of removing superfluous or damaged cells without eliciting an inflammatory response. It occurs during development and following chronic or acute cell and tissue damage.
Developmental pruning
A change in neuronal structure during development that removes unnecessary neurons or neuronal connections.
Reduced NGF signalling also results in the increased production and intracellular aggregation of Aβ peptides, which is mediated through increased transcription of APP and increased processing of APP by β-secretase and γ-secretases 81 . The pathogenic effects of altered TRK and p75NTR signalling in HD, however, are not well characterized (Supplementary information S1 (table) ).
Glucocorticoids have protective effects in the central nervous system, and this protection is dependent on an increase in TRK receptor activity 82 . Glucocorticoid treatment may therefore be beneficial in HD and AD, but this remains to be demonstrated using relevant disease models, as TRK receptors currently have low target-validation scores (FIG. 2; Supplementary information S1 (table) ).
Targeting apoptotic pathways
The caspase family of proteases are best known for their roles in apoptotic cell death, where they are activated either by extrinsic signals mediated through death receptors or intrinsic pathways initiated by DNA or mitochondrial damage 83 . Both pathways culminate in the activation of one or more members of the so-called executioner caspase subfamily (caspase 3, caspase 7 and caspase 6), which cleave cytoskeletal proteins as well as pro-survival and anti-apoptotic factors and thereby induce cell death 83 . However, in addition to this classical role, caspases are involved in non-apoptotic processes 84 . In the brain in particular, activation of the executioner caspases has been observed in events associated with learning and memory, such as synaptic plasticity and LTP, as well as in the developmental pruning of axons [85] [86] [87] [88] . These findings challenge the view that caspases are only the final executioners of cell death, and suggest that these enzymes may have a role upstream of the signalling pathways that are implicated in neurodegeneration, where they could mediate early neuronal dysfunction.
Preventing caspase 6 cleavage is beneficial in AD and HD. Caspase 6 has been shown to be activated in brain tissue samples taken from pre-symptomatic individuals carrying the HTT mutation and in individuals with only mild cognitive impairment (which can progress into AD), which supports the idea that caspase activation is an early event in the pathogenesis of neurodegenerative diseases 89, 90 . These findings are paralleled by results that show aberrant cleavage of caspase 6 substrates in brain tissue samples taken from patients with HD or AD [90] [91] [92] . Interestingly, the disease-causing proteins mutant HTT, tau and APP are substrates for caspase 6, and the abrogation of mutant HTT or APP cleavage in mouse models has a protective effect -leading to a dramatic improvement in the disease phenotype 93, 94 .
Therapeutic approaches. Although the findings discussed above make caspase 6 an interesting and wellvalidated target in the apoptotic pathway of both diseases (Supplementary information S2 (table)) , it may not be easily tractable by small-molecule inhibitors. The inhibition of executioner caspases by compounds such as IDN-6,556, compound 34 or M867 may also cause some liabilities, including carcinogenic side effects 95, 96 . An alternative would be to inhibit activators of caspase 6. However, the exact mechanism underlying aberrant caspase activation in AD and HD is not fully understood. It could occur through the activation of initiator caspases such as caspase 9, or via death or neurotrophic receptors such as death receptor 6 (also known as tumour necrosis factor superfamily member 1), p75NTR, TRKB or TRKA. As described above, alterations in these receptors occur in HD and AD, and neuronal death mediated through p75NTR in a seizure model is dependent on the downstream activation of caspase 6 (REF. 79) (FIG. 3) .
The intrinsic apoptotic pathway is another welldescribed paradigm for caspase activation, and it can be triggered by endoplasmic reticulum stress, protein misfolding (see below), as well as DNA and mitochondrial damage or oxidative stress 83 . Mutant HTT and Aβ can directly alter mitochondrial function in HD and AD. HTT can be found on the mitochondrial membrane 97 , and in the presence of mutant HTT oligomers the expression levels of proteins involved in mitochondrial fusion and fission are altered in mouse models of HD. These changes in the levels of protein expression may be responsible for decreased mitochondrial function by causing structural abnormalities in -and defective trafficking of -mitochondria in HD 97 . In AD, Aβ is accumulated in mitochondria -especially synaptic mitochondria -in an age-dependent manner 98, 99 , which enhances the permeability of the mitochondrial permeability transition pore and causes the generation of reactive oxygen species 99 . Clinical trials of antioxidants that might ameliorate oxidative stress, as well as DNA and mitochondrial damage, have not yielded conclusive results in patients with AD or HD 100, 101 . However, a better understanding of endogenous antioxidant levels in patients before and after treatment might help to stratify potential responders from non-responders 100 . Caspases can also be activated by disturbances in developmental and synaptic plasticity signals such as axonal pruning or LTP [85] [86] [87] [88] 102 . In these non-apoptotic paradigms, caspase activation is usually contained in a well-defined subcellular compartment such as the synapse, and the active executioner caspases are kept under tight control either by endogenous inhibitor proteins or through degradation by the proteasome 88, 103 . This ensures that the activation of enzymes -such as caspase 3 -that are usually highly efficient at amplifying the cell death cascade remains locally contained and does not trigger the death of the cell. Under pathological conditions, toxic proteins or fragments thereof (such as mutant HTT and Aβ) can cause proteasomal dysfunction, which might lead to impaired degradation and thus accumulation of active caspase 6 and caspase 3 (REF. 103 ). The resulting increase in caspase activity could then lead to an amplification of the apoptotic cascade and induce cell death, even though the initial caspase-activating signal was meant to only trigger non-apoptotic functions.
Further studies are needed to obtain a better understanding of the mechanisms involved in apoptotic pathways in AD and HD, and to more effectively validate therapeutic targets that are further upstream in the signalling cascade. 
Post-translational modification
A biochemical change made to a protein after the synthesis of the polypeptide chain is complete. This can include the attachment of lipids, carbohydrates, other small chemical entities (such as phosphate or acetate groups) or peptides (such as ubiquitin or small ubiquitin-related modifier), as well as the proteolytic cleavage of precursor proteins into functional fragments.
Targeting post-translational modifications
Although the proteolytic cleavage of mutant HTT and APP is a post-translational modification that is involved the pathogenesis of both disorders, additional reversible post-translational modifications of mutant HTT, Aβ and tau have been described 6, 9, 104 . These additional modifications lead to considerable overlap between potential therapeutic strategies targeting AD and HD, as discussed below.
Kinases and phosphatases. Both mutant HTT and APP are phosphorylated at multiple sites. Phosphorylation at specific amino acid residues (Ser421 for mutant HTT and Thr668 for APP) reduces the amount of caspasemediated cleavage at adjacent sites as well as the toxicity that is associated with this process 105, 106 . Mutant HTT is phosphorylated at Ser421 by AKT, and its dephosphorylation depends on the protein phosphatases PP1 and PP2A 107, 108 , whereas APP is phosphorylated by cyclin-dependent kinase 5 and GSK3β in neurons 104 (Supplementary information S3 (table)). GSK3β is also the major kinase that phosphorylates tau in AD, which leads to the formation of insoluble tau aggregates (known as tau tangles) and the subsequent disruption of the microtubule system 67 . The phosphatases that are responsible for the dephosphorylation of APP or tau have not yet been discovered.
Therapeutic strategies. Inhibition of GSK3β using lithium has a protective effect in mouse models of AD. This protection has been partly attributed to a decrease in tau hyperphosphorylation and improved BDNF trafficking (as described above) as well as a reduction in APP cleavage and Aβ accumulation, as the GSK3α isoform has been implicated in the processing of APP by γ-secretase 67, 109 . Lithium treatment is also beneficial in mouse models of HD 57, 110 , and levels of GSK3β are increased before the onset of disease symptoms 111 . The treatment of primary neurons derived from mouse models of HD with GSK3β inhibitors reduces neuronal death 111 (Supplementary information S3 (table) ). Sodium valproate, which is widely used as a mood stabilizer and anti-epileptic drug, has promising neuroprotective effects in several mouse models of AD 112 . It inhibits GSK3β, but has additional effects by acting as a transcriptional modulator (through the inhibition of HDACs) and by reducing excitotoxicity 110, 113 . Although sodium valproate might not be suitable for the management of agitation in dementia 114 , longer-term studies are necessary to ascertain its neuroprotective effects.
Inhibition of PP1 and PP2A is a possible strategy to boost the phosphorylation of mutant HTT in HD and thus reduce its toxicity 108 . As illustrated by the low target-validation score of phosphatases (Supplementary information S3 (table)), further studies are needed before phosphatase inhibition can be pursued as a therapeutic option. Notably, the identity of the regulatory subunits of PP1 and PP2A that mediate HTT dephosphorylation remains unknown. The inhibition of these regulatory subunits might be a more successful strategy than the development of active-site inhibitors, as the active phosphatase subunits are considerably promiscuous in terms of substrate specificity 115 . Conversely, upregulation of AKT activity could be achieved through modulation of the insulin-like growth factor 1 and PI3K signalling pathway upstream of AKT 107 . This pathway has also emerged as a target in the upregulation of autophagy in AD and HD.
Palmitoylation: palmitoyl transferases and thioesterases as targets. Palmitoylation [116] [117] [118] [119] , a post-translational modification that attaches a single palmitate moiety to a cysteine residue, is important in synaptic transmission and neuronal plasticity 120 . In AD the palmitoylation of β-secretase reduces the shedding of the ectodomain of the protease, which in turn reduces the formation of Aβ 119 . The HTT protein itself is palmitoylated by the palmitoyl transferases huntingtin-interacting protein 14 (HIP14; also known as ZDHHC17) and the related Figure 3 | Therapeutic targets in the apoptotic pathway. The aberrant activation of caspase 6 that is seen in animal models and in patients with either Huntington's disease (HD) or Alzheimer's disease (AD) could be mediated through multiple pathways. Excitotoxicity leads to an excessive influx of calcium, which can depolarize mitochondrial membranes and lead to caspase activation. Aberrant signalling through trophic receptors or death receptors (such as death receptor 6 (DR6)) can result in the release of cytochrome c and second mitochondria-derived activator of caspase (SMAC) from mitochondria, which activate caspase 9 and inhibit the apoptosis regulator B cell lymphoma 2 as well as inhibitor of apoptosis proteins (IAPs). These events lead to a subsequent activation of caspase 6, either by blocking inhibitory pathways and/or through direct activation of caspase 9. Furthermore, caspase 6 and caspase 3 could be activated through the intrinsic pathway, as evidence for DNA and mitochondrial damage, endoplasmic reticulum (ER) stress, protein misfolding and oxidative stress has been observed in patients with AD or HD, as well as in animal models. Degradation of caspase 6 through the proteasome reduces its activity. p75NTR, low-affinity nerve growth factor receptor; TRKA, neurotrophic tyrosine kinase receptor 1.
protein HIP14L (also known as ZDHHC13) 117 , and acts as a cofactor for the palmitoylation of other HIP14 substrates 121 . The interaction of mutant HTT with HIP14 is reduced in a mouse model of HD 118 . The resulting decrease in the palmitoylation of several synaptic substrates could lead to the phenotype that is observed in HD 121 (Supplementary information S3 (table)) . Furthermore, the ablation of HIP14 in a mouse model leads to a phenotype similar to HD 122 . An increase in palmitoyl transferase activity or thioesterase inhibition could therefore be beneficial by reducing Aβ generation in AD and by normalizing the aberrant palmitoylation of numerous synaptic substrates in HD. However, because of the lack of information on the palmitoyl transferase (or transferases) involved in β-secretase palmitoylation and the thioesterases involved in the depalmitoylation of HTT or β-secretase, further studies are warranted before targeted therapies to correct palmitoylation defects can be developed.
Aberrant protein acetylation and HDACs. Both AD and HD are associated with transcriptional dysregulation that is linked to altered histone acetylation, and defective axonal transport that is due to a lack of tubulin acetylation 69, 123 . These defects could account for several of the disease phenotypes that are associated with AD and HD, such as the altered expression and transport of neurotrophic factors 124 , and might therefore be upstream events in the pathogenic pathways of both disorders.
As a therapeutic strategy to increase acetylation, the inhibition of HDACs by compounds such as phenyl butyrate, trichostatin A or suberoylanilide hydroxamic acid (also known as vorinostat) (Zolinza, Merck) has a protective effect in cellular and animal models of AD and HD 69, 125, 126 (Supplementary information S3 (table) ). HDAC inhibitors such as suberoylanilide hydroxamic acid or valproic acid are currently in Phase II/III clinical trials for different types of cancer (ClinicalTrials. gov identifiers: NCT00128102; NCT01386398; NCT00773747; NCT00262834; and NCT00977132), which -together with the high degree of target validation for HDACs -makes them good candidates for clinical trials in neurodegenerative diseases.
Protein aggregation and clearance mechanisms
Protein aggregation is a neuropathological hallmark of AD and HD that has been recognized for many decades. In HD this involves the deposition of intracellular and intranuclear aggregates of mutant HTT, whereas in AD it involves the accumulation of extracellular Aβ plaques and intracellular tau tangles 127 . The accumulation of misfolded proteins that have amyloid characteristics (a tertiary structure that is rich in β-sheets and can be visualized by staining with dyes such as Congo red and thioflavin S) is thought to result from improper folding of the mutant proteins as well as insufficient clearance mechanisms 128 . Endogenous chaperones, in particular the heat shock proteins, prevent the misfolding and aggregation of mutant HTT, tau and Aβ 129 , and their overexpression is protective against neurotoxic insults such as excitotoxicity 130 ( Supplementary information S4 (table) ).
Targeting protein misfolding directly and/or through chaperones. Screening campaigns have led to the identification of several compounds that directly interfere with the misfolding and aggregation of Aβ, mutant HTT and tau in cell-free systems, as well as compounds that modulate the activity of heat shock proteins and other chaperones [131] [132] [133] [134] [135] [136] [137] (FIG. 4) . However, for both classes of compounds the translation of therapeutic efficacy into mouse models has been difficult.
Geldanamycin, a compound that is highly efficient in the upregulation of chaperone proteins and can thus reduce amyloid formation in cell culture, has the drawback of having substantial toxicity and low blood-brain barrier penetration. Another example is epigallocatechin-3-gallate, a compound that has a beneficial effect in patients suffering from systemic amyloidosis by reducing the amount of aggregated protein in tissues such as the heart 138 . It stabilizes the non-toxic forms of both mutant HTT and Aβ (which have a low β-sheet content) 133, 134 , and although some studies report beneficial effects of this compound in animal models of AD 139 , its delivery into the central nervous system is difficult 140 . Lack of translation of the effects seen in cell culture into mouse models has also been attributed to the high drug-amyloid protein ratios that need to be achieved to directly modulate protein aggregation.
A major limitation of the development of inhibitors of protein aggregation is an incomplete understanding of the protein misfolding and aggregation pathway. Although early studies focused on preventing the formation of large amyloid aggregates, it is now clear that misfolding events that occur at an early stage in the amyloidogenic process lead to the generation of monomers or small oligomers that can mediate neurotoxicity and degradation 141, 142 . Owing to the difficulties associated with detecting these smaller toxic monomers or oligomers, the exact mechanism of action for many aggregation inhibitors -such as the benzothiazoles, C2-8 or triazines -remains unknown. Moreover, although they prevent the formation of large Aβ plaques and mutant HTT aggregates 131, 132, 135 , these inhibitors might not interfere with the initial misfolding steps and thus they will not have a substantial impact on the pathogenesis of AD and HD (FIG. 4) .
Proof of the therapeutic benefits of inhibitors of protein aggregation through studies in mammalian models of AD and HD is therefore necessary to increase their target-validation score (Supplementary information S4  (table) ). Such studies would also ascertain whether the prevention of protein aggregation alone is sufficient to slow down the pathogenesis of AD and HD.
Increasing the clearance of misfolded proteins: the ubiquitin-proteasome system as a target. Intracellular aggregates of mutant HTT and tau contain high levels of ubiquitin; this led to the hypothesis that the proteasomal degradation of ubiquitylated proteins could be impaired in HD and AD, and that this might lead to the accumulation of amyloid aggregates 143, 144 . There is conflicting evidence for an impairment of the ubiquitinproteasome system in HD and AD. A time-lapse study
Macroautophagy
The second major degradation pathway that can be used to degrade proteins, protein aggregates and entire organelles. Substrates are engulfed by vesicles (autophagosomes) that later fuse with lysosomal vesicles that have proteolytic activity. Degradation occurs in the final autophagolysosome.
of single neurons expressing mutant HTT showed that the ubiquitin-proteasome system is impaired before the formation of visible aggregates. However, the function of the ubiquitin-proteasome system normalizes at later time points in the presence of aggregates 145 . Recent studies further show that the ubiquitin-proteasome system has an important function in the degradation of signalling molecules at the synapse, and contributes to synaptic plasticity 146 . As synaptic dysfunction occurs at an early stage in the pathogenesis of neurodegenerative diseases, it is possible that localized impairment of the ubiquitin-proteasome system has an important role in the accumulation of misfolded proteins, even if the overall function of the ubiquitin-proteasome system at other subcellular localizations remains intact 147 . Although the ubiquitin-proteasome system is a popular target in cancer, where its activity is reduced by compounds such as bortezomib (Velcade, Millennium Pharmaceuticals) 148 , upregulation of proteasomal degradation by a small molecule has only recently been reported 149 . It will be interesting to follow the further development of such compounds and monitor their effects in rodent models of HD and AD, as they are valuable tools for additional validation of the ubiquitinproteasome system as a therapeutic target.
Lysosomal proteases as therapeutic targets.
Macroautophagy is also an important pathway for the elimination of toxic or misfolded proteins. Protein degradation in the autophagic pathway takes place following the fusion of the autophagosome with lysosomes, and these vesicles are known sites of pathology in AD and HD (FIG. 5) . Aβ can be generated from APP in autophagic vesicles via its cleavage by γ-secretase, and these vesicles accumulate in dystrophic neurites in patients with AD as well as in mouse models 150 . PSEN1 is not only an essential part of the γ-secretase complex in lysosomes but also necessary for maintaining an acidic pH in these vesicles, which in turn is required to guarantee the degradation of protein cargo 151 . PSEN1 mutations that are linked to FAD impair this function, leading to the accumulation of vesicles containing Aβ 151 . After the fusion of the autophagosome with the lysosome, proteases of the cathepsin family break down cargo proteins (FIG. 5) . The genetic deletion of an endogenous inhibitor of cathepsins -cystatin B -ameliorates the memory deficits and decreases Aβ aggregate load in a mouse model of AD 152 , which indicates that lysosomal proteases are able to clear disease-causing proteins in AD and that their upregulation should have a beneficial effect (Supplementary information S4 (table) ). It was proposed that the expression of mutant HTT in HD impairs vesicular transport from the Golgi to the lysosomes and thus leads to a reduction in the levels of lysosomal cathepsins 153 (FIG. 5) , which would result in inefficient autophagy in HD. Cystatin B knockdown in mouse models of HD and studies with cathepsin inhibitors in animal models of AD and HD could help to further confirm and validate these therapeutic targets.
Targeting the PI3K and BECN1 pathway. The beclin 1 (BECN1)-PI3K complex influences autophagy through the modulation of autophagosome formation, maturation and degradation 154 (FIG. 5) . In a mouse model of AD the loss of BECN1 leads to the accumulation of Aβ plaques and lysosomes, as well as neuronal loss 154 . A reduction in the levels of BECN1 leads to the accumulation of mutant HTT and reduces the viability of a mouse model of HD 155 . The autophagic response initiated by the exposure of cultured cells to Aβ is mediated by PI3K 156 , and a similar induction of autophagy through PI3K activity occurs in cell-culture models of HD 157 . Conversly, blocking autophagy through the pharmacological inhibition of PI3K activity by 3-methyl adenine increases the levels of mutant HTT and reduces the viability of cells expressing mutant HTT 158 . Preservation or upregulation of the function of PI3K and BECN1, which normally declines with age 155 , is therefore a promising strategy for increasing the degradation of mutant HTT and Aβ (Supplementary information S4 (table)), although pharmacological agents that could achieve this effect are currently not available. However, BECN1 gene transfer has been used Figure 4 | Therapeutic targets in the protein misfolding pathway. The disease-causing proteins mutant huntingtin (HTT), microtubule-associated protein tau and amyloid-β (Aβ) undergo misfolding and aggregation, which is a multistep process involving misfolded monomers, oligomers and large aggregate structures. Endogenous chaperone proteins from the heat shock protein (HSP) family can inhibit aggregation and probably interfere with protein misfolding and aggregation at different steps of the protein misfolding and aggregation pathway. HSPs (such as HSP70, HSP40 and HSP104) can be transcriptionally upregulated through heat shock factor protein 1 (HSF1), which in turn is activated by compounds such as celastrol or geldanamycin that reduce protein aggregation and toxicity in cell cultures and in Drosophila melanogaster models of Alzheimer's disease and Huntington's disease. Chemical compounds that directly interfere with the aggregation cascade are often identified as inhibitors of aggregate formation and, with the exception of epigallocatechin-3-gallate (EGCG), the precise step at which they interfere with the aggregation cascade is unknown. Targeting mTOR to modulate autophagy. Mammalian target of rapamycin (mTOR) negatively regulates autophagy through the phosphorylation of its target proteins UNC51-like kinase 1 and autophagy-related protein 13 (REF. 160 ), which prevents the formation of autophagosomes 160 (FIG. 5) . The mTOR inhibitors rapamycin (also known as sirolimus) (Rapamune; Pfizer) and its analogues everolimus (Afinitor; Novartis) and temsirolimus (Torisel, Pfizer) increase the autophagic clearance of mutant HTT and Aβ. This has been associated with decreased toxicity in cellular models and the rescue of different disease phenotypes in animal models of AD and HD 161, 162 (Supplementary information S4 (table) ). These drugs are approved for the prevention of organ transplant rejection and for the treatment of different forms of cancer, and preclinical trials have been carried out for several autoimmune and infectious diseases (reviewed in REF. 163 ). However, haematological side effects are common and often lead to the termination of treatment 163 , so the long-term use of these drugs for HD or AD is unlikely.
An additional pathway for the induction of autophagy has been described, which is independent of mTOR activity and mediated through the inhibition of inositol monophosphatase and the subsequent reduction in inositol or inositol-1,4,5-trisphosphate levels 164 . This inhibition can be therapeutically achieved using lithium or valproate, and has been shown to be beneficial in Drosophila melanogaster and zebrafish models of HD 164 (FIG. 5) . Lithium has additional effects on neurotrophic factors and tau phosphorylation, and although an initial short-term clinical trial in patients with AD did not result in altered levels of phosphorylated tau 165 , a potential disease-modifying effect has been shown in a longerterm study 55 . Moreoever, the so-called small-molecule enhancers of rapamycin are a series of compounds that induce autophagy in neurons independently of mTOR 166 , and were protective in a Drosophila melanogaster model of HD through an effect that was also independent or downstream of mTOR 167 . In summary, the autophagic pathway contains several well-validated targets (with target-validation scores of 3.0 or higher) that are involved in the pathogenesis of AD and HD. Although the inhibition of mTOR has been studied in great detail, the application of currently available compounds that inhibit autophagy is hampered by severe side effects. If no alternative compounds can be developed, other avenues such as the stabilization of BECN1 could be pursued to increase the autophagic clearance of disease-causing proteins in AD and HD.
Efficient clinical trials through predictive testing
The design of clinical trials for patents with AD has often been criticized for only including patients in late stages of the disease, in whom substantial neurodegeneration has already occurred, or for including patients who Figure 5 | Therapeutic targets in the autophagy pathway. Upregulation of autophagy is an efficient way to clear disease-causing proteins in Alzheimer's disease (AD) and Huntington's disease (HD), and therapeutic interventions have been tested against several targets. The balance between inhibition of autophagy by AKT and its activation by AMP-activated protein kinase (AMPK) is shifted using resveratrol analogues, which increase AMPK activity. Inhibition of glycogen synthase kinase 3β (GSK3β) using lithium prevents excessive phosphorylation of microtubule-associated protein tau and allows pro-survival cyclic AMP-responsive element-binding protein (CREB) signalling; this consequently results in increased autophagy through inhibition of the inositol monophosphatase (IMPase) pathway. Inhibition of mammalian target of rapamycin (mTOR) with rapamycin and analogue compounds lifts the block on autophagosome formation, and these compounds are beneficial in mouse models of both AD and HD. An mTOR-independent pathway that activates autophagy can be triggered by treatment with valproate, and this pathway leads to a decrease in inositol and inositol-1,4,5-trisphosphate (Ins(1,4,5)P 3 ) levels. The beclin 1-phosphoinositide 3-kinase (PI3K) complex promotes autophagosome formation, and the loss or inhibition of either protein is detrimental in mouse and cell-culture models of AD and HD. Autophagosomes not only engulf aggregates of disease-causing proteins that are present in the cytoplasm but also generate Aβ through γ-secretase-mediated cleavage of APP. Upon fusion with the lysosome, the autophagosome becomes acidic, and lysosomal proteases such as the cathepsins degrade the disease-causing proteins. Genetic deletion of the endogenous cathepsin inhibitor cystatin B is beneficial in a mouse model of AD. Furthermore, mutant huntingtin (HTT) interferes with lysosome function by impairing vesicle transport from the Golgi, resulting in a decrease in levels of proteases in the lysosome. Presenilin 1 (PSEN1) deletion or mutations interfere with the acidification of the lysosome, thus reducing the activity of lysosomal proteases and rendering autophagy-mediated protein degradation less efficient. APP, amyloid precursor protein; IGF1, insulin-like growth factor 1; TSC1, tuberous sclerosis 1; V-ATPase, vacuolar ATPase.
suffer from other forms of dementia instead of AD 168 . There has been substantial progress in the development of biomarkers to reliably diagnose early-stage AD and monitor disease progression. Although levels of total tau, phosphorylated tau and Aβ in the cerebrospinal fluid yield reasonable sensitivity (95%) and specificity (83%) 169 , these measures still show considerable variability and so the accurate identification of patients with early-stage AD is difficult 170 . The monogenic cause of HD, however, makes it possible to determine the effect of therapeutic interventions on the onset of disease symptoms in patients who do not yet show substantial neuronal loss. In HD a more homogeneous disease phenotype, better-defined clinical end points and longitudinal markers of disease progression that are currently being established allow the disease-modifying effects of therapeutics to be assessed in a time frame of 1-2 years 16 . In our opinion, compounds that show efficacy in patients with HD could be prioritized for clinical trials in patients with AD, whereas drugs that do not show efficacy in patients with HD could be given lower priority. However, the development of reliable biomarkers that are correlated with early stages of the disease remains a challenge to conducting clinical trials for AD. Currently, therapeutic interventions are being tested in patients with mild cognitive impairment, and their progression to clinically manifest AD is being monitored 55 . Therapeutics that have been beneficial in clinical trials of patients with HD would provide proof of concept that the targeted pathway can be modulated, and could similarly be assessed.
Despite the numerous common therapeutic targets that have been identified for AD and HD, it is unknown why the phenotype of both diseases is different, with different brain areas affected, different sets of proteins misfolded and accumulated, as well as different clinical symptoms observed. The most obvious explanation is the difference in underlying genetic mutations: the aetiology of HD is defined by the expression of the mutant HTT protein, whereas AD is largely of unknown aetiology or -in rare cases -caused by mutations in APP, PSEN1 or PSEN2. Differences in the expression patterns of these crucial proteins -including HTTas well as alterations in protein-protein interactions could account for the susceptibility of distinct neuronal subpopulations to degeneration and death, which are in turn correlated with the major clinical symptoms of chorea in HD or dementia in AD. Although mutant HTT, APP, PSEN1 and PSEN2 are therapeutic targets in their own right, the dysfunction of these proteins triggers the activation of pathogenic pathways that are shared between AD and HD and that constitute promising therapeutic targets. We believe that the modulation of these targets is likely to be possible using the same therapeutic strategy for both diseases (TABLE 3) , and that these interventions will also result in similar side effects for both patient subpopulations.
Overall, the convergence of pathways that are shared between AD and HD should encourage greater interaction between scientists from both AD and HD research communities, as lessons learned from one disorder may have an impact on the other disorder. 
